The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown. ⋯ In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation. (Funded by ARCAGY Research and others; PAOLA-1 ClinicalTrials.gov number, NCT02477644.).
-
Editorial Comment
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.